Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD

REVIVE Trial : Dara + Bispecific in High-Risk Smoldering Myeloma | Ola Landgren, MD, PhD

New Talquetamab Combos Show Promise for Longer-Lasting Myeloma Control | Jeffrey Matous, MD

Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD

Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD

Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD

Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD

Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD

First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD

Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD

Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD

Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD

Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD

Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD

Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD

Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD

Targeting t(4; 14) Myeloma with a New Oral MMSET Inhibitor | Saad Usmani, MD

Fewer Injections, Same-Day Collection: A New Option Before Transplant | Jack Khouri, MD

Sonrotoclax Combo Shows Promise for 11;14 Myeloma | Hang Quach, MD

How Doctors Spot Hidden Myeloma Risks Early | Bruno Paiva, PhD